Sanofi (EPA: SAN) recently received a number of ratings updates from brokerages and research firms:

  • 2/8/2018 – Sanofi was given a new €94.00 ($116.05) price target on by analysts at Societe Generale. They now have a “buy” rating on the stock.
  • 2/8/2018 – Sanofi was given a new €93.00 ($114.81) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 2/8/2018 – Sanofi was given a new €95.00 ($117.28) price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 2/7/2018 – Sanofi was given a new €82.00 ($101.23) price target on by analysts at Sanford C. Bernstein. They now have a “neutral” rating on the stock.
  • 2/7/2018 – Sanofi was given a new €97.00 ($119.75) price target on by analysts at Berenberg Bank. They now have a “neutral” rating on the stock.
  • 2/7/2018 – Sanofi was given a new €82.00 ($101.23) price target on by analysts at Goldman Sachs Group Inc. They now have a “neutral” rating on the stock.
  • 2/6/2018 – Sanofi was given a new €83.00 ($102.47) price target on by analysts at Kepler Capital Markets. They now have a “buy” rating on the stock.
  • 1/30/2018 – Sanofi was given a new €82.00 ($101.23) price target on by analysts at UBS Group AG. They now have a “neutral” rating on the stock.
  • 1/30/2018 – Sanofi was given a new €93.00 ($114.81) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 1/29/2018 – Sanofi was given a new €82.00 ($101.23) price target on by analysts at Goldman Sachs Group Inc. They now have a “neutral” rating on the stock.
  • 1/23/2018 – Sanofi was given a new €100.00 ($123.46) price target on by analysts at Societe Generale. They now have a “buy” rating on the stock.
  • 1/23/2018 – Sanofi was given a new €78.00 ($96.30) price target on by analysts at S&P Global. They now have a “neutral” rating on the stock.
  • 1/23/2018 – Sanofi was given a new €82.00 ($101.23) price target on by analysts at Goldman Sachs Group Inc. They now have a “neutral” rating on the stock.
  • 1/23/2018 – Sanofi was given a new €65.00 ($80.25) price target on by analysts at Barclays PLC. They now have a “sell” rating on the stock.
  • 1/22/2018 – Sanofi was given a new €97.00 ($119.75) price target on by analysts at Berenberg Bank. They now have a “neutral” rating on the stock.
  • 1/19/2018 – Sanofi was given a new €93.00 ($114.81) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 1/16/2018 – Sanofi was given a new €80.00 ($98.77) price target on by analysts at Jefferies Group LLC. They now have a “neutral” rating on the stock.

Sanofi SA (SAN) traded down €1.70 ($2.10) during trading on Friday, hitting €63.39 ($78.26). 4,980,000 shares of the company’s stock were exchanged, compared to its average volume of 2,940,000. Sanofi SA has a 12-month low of €63.09 ($77.89) and a 12-month high of €92.97 ($114.78). The company has a market capitalization of $80,070.00 and a price-to-earnings ratio of 20.99.

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.